866-997-4948(US-Canada Toll Free)

Fibrosarcoma - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Mar 2017

Category :

Pharmaceutical

No. of Pages : 57 Pages

Fibrosarcoma - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosarcoma Pipeline Review, H1 2017, provides an overview of the Fibrosarcoma (Oncology) pipeline landscape.

Fibrosarcoma is a malignant tumor derived from fibrous connective tissue. Symptoms include local pain, local swelling, local warmth, dilated blood vessels pain and swelling of the bone, pathological fractures, neurological and vascular changes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrosarcoma Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fibrosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fibrosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 7 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Fibrosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Fibrosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fibrosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fibrosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosarcoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fibrosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fibrosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fibrosarcoma Overview
Fibrosarcoma Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fibrosarcoma Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibrosarcoma Companies Involved in Therapeutics Development
Advanced Proteome Therapeutics Corp
Advenchen Laboratories LLC
Bicycle Therapeutics Ltd
Daiichi Sankyo Company Ltd
Elsalys Biotech SAS
Intezyne Technologies Inc
Novartis AG
Pharma Mar SA
SOM Biotech SL
Sumitomo Dainippon Pharma Co Ltd
Fibrosarcoma Drug Profiles
AL-3818 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Inhibit Rho-GAP for Colon Cancer and Fibrosarcoma Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APC-103 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-1718 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Oncology Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daunorubicin hydrochloride Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSR-6434 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELB-021 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
everolimus Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LK-3 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MI-130110 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-7486 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SEN-461 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOM-0777 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fibrosarcoma Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Fibrosarcoma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Fibrosarcoma Pipeline by Advanced Proteome Therapeutics Corp, H1 2017
Fibrosarcoma Pipeline by Advenchen Laboratories LLC, H1 2017
Fibrosarcoma Pipeline by Bicycle Therapeutics Ltd, H1 2017
Fibrosarcoma Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Fibrosarcoma Pipeline by Elsalys Biotech SAS, H1 2017
Fibrosarcoma Pipeline by Intezyne Technologies Inc, H1 2017
Fibrosarcoma Pipeline by Novartis AG, H1 2017
Fibrosarcoma Pipeline by Pharma Mar SA, H1 2017
Fibrosarcoma Pipeline by SOM Biotech SL, H1 2017
Fibrosarcoma Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
Fibrosarcoma Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Fibrosarcoma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *